Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Astellas Pharma (United States) · Universitat de València · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
240
total citations
- FWCI
- 42.91
- Percentile
- 100%
- References
- 29
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Vasomotor
- Medicine
- Placebo
- Menopause
- Clinical trial
- Randomized controlled trial
- Physical therapy
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.